News | October 23, 2022
Jubilant Pharmova Q2FY23 consolidated PAT drops to Rs. 5.49 Cr
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
With the receipt of the EIR, the inspection stands successfully closed.
he US FDA has issued six observations pursuant to the completion of the audit.
Post this currently only Risperidone orally disintegrating tablets are allowed for import into the US from the Roorkee facility.
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)